Explore
Validate
Learn
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [18]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB347-100 - Provider product page
- Provider
- R&D Systems
- Product name
- Human TRAILR1/TNFRSF10A Antibody
- Antibody type
- Monoclonal
- Description
- Protein A or G purified from hybridoma culture supernatant. Detects recombinant human TRAIL R1/TNFRSF10A in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) TRAIL R2, rhTRAIL R3, rhTRAIL R4, or rhDcR3 is observed.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Antigen sequence
AAC51226- Isotype
- IgG
- Antibody clone number
- 69036
- Vial size
- 100 ug
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps.
Targeting Apoptotic Activity Against Prostate Cancer Stem Cells.
Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes.
TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells.
Casticin potentiates TRAIL-induced apoptosis of gastric cancer cells through endoplasmic reticulum stress.
Exosomes secreted by human placenta carry functional Fas ligand and TRAIL molecules and convey apoptosis in activated immune cells, suggesting exosome-mediated immune privilege of the fetus.
The transmembrane domains of TNF-related apoptosis-inducing ligand (TRAIL) receptors 1 and 2 co-regulate apoptotic signaling capacity.
TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells.
Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response.
Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL).
Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients.
Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.
P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
Differential responses of FLIPLong and FLIPShort-overexpressing human myeloid leukemia cells to TNF-alpha and TRAIL-initiated apoptotic signals.
Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms.
A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage.
HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma.
Danish L, Imig D, Allgöwer F, Scheurich P, Pollak N
PloS one 2018;13(6):e0198203
PloS one 2018;13(6):e0198203
Targeting Apoptotic Activity Against Prostate Cancer Stem Cells.
Jaworska D, Szliszka E
International journal of molecular sciences 2017 Jul 29;18(8)
International journal of molecular sciences 2017 Jul 29;18(8)
Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes.
Neumann S, Hasenauer J, Pollak N, Scheurich P
The Journal of biological chemistry 2014 Jun 6;289(23):16576-87
The Journal of biological chemistry 2014 Jun 6;289(23):16576-87
TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells.
Tang XJ, Lu JT, Tu HJ, Huang KM, Fu R, Cao G, Huang M, Cheng LH, Dai LJ, Zhang L
Anticancer research 2014 Feb;34(2):729-34
Anticancer research 2014 Feb;34(2):729-34
Casticin potentiates TRAIL-induced apoptosis of gastric cancer cells through endoplasmic reticulum stress.
Zhou Y, Tian L, Long L, Quan M, Liu F, Cao J
PloS one 2013;8(3):e58855
PloS one 2013;8(3):e58855
Exosomes secreted by human placenta carry functional Fas ligand and TRAIL molecules and convey apoptosis in activated immune cells, suggesting exosome-mediated immune privilege of the fetus.
Stenqvist AC, Nagaeva O, Baranov V, Mincheva-Nilsson L
Journal of immunology (Baltimore, Md. : 1950) 2013 Dec 1;191(11):5515-23
Journal of immunology (Baltimore, Md. : 1950) 2013 Dec 1;191(11):5515-23
The transmembrane domains of TNF-related apoptosis-inducing ligand (TRAIL) receptors 1 and 2 co-regulate apoptotic signaling capacity.
Neumann S, Bidon T, Branschädel M, Krippner-Heidenreich A, Scheurich P, Doszczak M
PloS one 2012;7(8):e42526
PloS one 2012;7(8):e42526
TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells.
Moniri MR, Sun XY, Rayat J, Dai D, Ao Z, He Z, Verchere CB, Dai LJ, Warnock GL
Cancer gene therapy 2012 Sep;19(9):652-8
Cancer gene therapy 2012 Sep;19(9):652-8
Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response.
Kang Z, Chen JJ, Yu Y, Li B, Sun SY, Zhang B, Cao L
Clinical cancer research : an official journal of the American Association for Cancer Research 2011 May 15;17(10):3181-92
Clinical cancer research : an official journal of the American Association for Cancer Research 2011 May 15;17(10):3181-92
Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL).
Zauli G, Rimondi E, Celeghini C, Milani D, Secchiero P
Journal of cellular physiology 2010 Feb;222(2):357-64
Journal of cellular physiology 2010 Feb;222(2):357-64
Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients.
Stary G, Klein I, Kohlhofer S, Koszik F, Scherzer T, Müllauer L, Quendler H, Kohrgruber N, Stingl G
Blood 2009 Oct 29;114(18):3854-63
Blood 2009 Oct 29;114(18):3854-63
Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.
Barbarotto E, Corallini F, Rimondi E, Fadda R, Mischiati C, Grill V, Vaccarezza M, Celeghini C
Journal of cellular biochemistry 2008 May 15;104(2):595-605
Journal of cellular biochemistry 2008 May 15;104(2):595-605
P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
Toscano F, Fajoui ZE, Gay F, Lalaoui N, Parmentier B, Chayvialle JA, Scoazec JY, Micheau O, Abello J, Saurin JC
Oncogene 2008 Jul 10;27(30):4161-71
Oncogene 2008 Jul 10;27(30):4161-71
Differential responses of FLIPLong and FLIPShort-overexpressing human myeloid leukemia cells to TNF-alpha and TRAIL-initiated apoptotic signals.
Seal S, Hockenbery DM, Spaulding EY, Kiem HP, Abbassi N, Deeg HJ
Experimental hematology 2008 Dec;36(12):1660-72
Experimental hematology 2008 Dec;36(12):1660-72
Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms.
Shankar S, Chen Q, Ganapathy S, Singh KP, Srivastava RK
Molecular cancer therapeutics 2008 Aug;7(8):2328-38
Molecular cancer therapeutics 2008 Aug;7(8):2328-38
A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
Weinmann L, Wischhusen J, Demma MJ, Naumann U, Roth P, Dasmahapatra B, Weller M
Cell death and differentiation 2008 Apr;15(4):718-29
Cell death and differentiation 2008 Apr;15(4):718-29
Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage.
Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy PT, Lampertico P, Das A, Lopes AR, Borrow P, Williams K, Humphreys E, Afford S, Adams DH, Bertoletti A, Maini MK
The Journal of experimental medicine 2007 Mar 19;204(3):667-80
The Journal of experimental medicine 2007 Mar 19;204(3):667-80
HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma.
Singh TR, Shankar S, Srivastava RK
Oncogene 2005 Jul 7;24(29):4609-23
Oncogene 2005 Jul 7;24(29):4609-23
No comments: Submit comment
No validations: Submit validation data